Investigational Drug Information for Tesetaxel
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Tesetaxel?
Tesetaxel is an investigational drug.
There have been 16 clinical trials for Tesetaxel.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2017.
The most common disease conditions in clinical trials are Breast Neoplasms, Stomach Neoplasms, and Neoplasms. The leading clinical trial sponsors are Genta Incorporated, Odonate Therapeutics, Inc., and M.D. Anderson Cancer Center.
There are six hundred and sixty-five US patents protecting this investigational drug and six international patents.
Summary for Tesetaxel
| US Patents | 665 |
| International Patents | 6,679 |
| US Patent Applications | 1,533 |
| WIPO Patent Applications | 1,063 |
| Japanese Patent Applications | 659 |
| Clinical Trial Progress | Phase 2 (2017-12-21) |
| Vendors | 14 |
Recent Clinical Trials for Tesetaxel
| Title | Sponsor | Phase |
|---|---|---|
| The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors | Odonate Therapeutics, Inc. | Phase 1 |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | Odonate Therapeutics, Inc. | Phase 2 |
| Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC | Odonate Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for Tesetaxel
Top disease conditions for Tesetaxel
Top clinical trial sponsors for Tesetaxel
US Patents for Tesetaxel
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tesetaxel | See Plans and Pricing | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | See Plans and Pricing |
| Tesetaxel | See Plans and Pricing | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Tesetaxel | See Plans and Pricing | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | See Plans and Pricing |
| Tesetaxel | See Plans and Pricing | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH (Darmstadt, DE) | See Plans and Pricing |
| Tesetaxel | See Plans and Pricing | Method of reducing blood glucose by administering RON agonists | GENENTECH, INC. (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tesetaxel
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tesetaxel | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | See Plans and Pricing |
| Tesetaxel | Australia | AU2015231053 | 2034-03-21 | See Plans and Pricing |
| Tesetaxel | Brazil | BR112016021620 | 2034-03-21 | See Plans and Pricing |
| Tesetaxel | Canada | CA2943339 | 2034-03-21 | See Plans and Pricing |
| Tesetaxel | China | CN106231900 | 2034-03-21 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
